

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>A61M 15/00, 37/00, B65D 35/28, 83/00</b>	<b>A1</b>	(11) International Publication Number: <b>WO 96/40334</b> (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: <b>PCT/US96/08083</b>		(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: <b>3 June 1996 (03.06.96)</b>		
(30) Priority Data: <b>484,279</b> 7 June 1995 (07.06.95) US		
(71) Applicant: WAYNE STATE UNIVERSITY [US/US]; 4043 Faculty/Administration Building, Detroit, MI 48202 (US).		Published <i>With international search report.</i>
(72) Inventors: SPEARS, James, R.; 615 Bridle Path Court, Bloomfield Hills, MI 48304 (US). CRILLY, Richard, J.; 935 Bartlet, Wondson, Ontario N9G 1V3 (CA).		
(74) Agents: STARK, Jon, R. et al; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).		

(54) Title: DELIVERY OF OXYGEN-SUPERSATURATED PHYSIOLOGIC SOLUTIONS



(57) Abstract

An apparatus (10) and method for delivering an oxygen-supersaturated physiologic solution (12) into a lumen (14) of a blood vessel (16) to replace arterial blood beyond an angioplasty catheter (22) during clinical angioplasty without bubble formation.

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**DELIVERY OF OXYGEN SUPERSATURATED PHYSIOLOGIC SOLUTIONS****Cross Reference To Related Applications**

5        This application is a continuation-in-part of application Serial No. 08/353,137, filed on December 9, 1994, which is a continuation-in-part of application Serial No. 08/273,652, filed July 12, 1994, which is a continuation-in-part of application Serial No. 10      08/152,589, filed November 15, 1993 (now U.S. Pat. No. 5,407,426), which is a continuation-in-part of application Serial No. 07/818,045, filed January 8, 1992 (now U.S. Pat. No. 5,261,875), which is a continuation 15      of application Serial No. 07/655,078, filed February 14, 1991 (now U.S. Pat. No. 5,086,620). The disclosures in each of the above-referenced cases are incorporated herein by reference.

**Technical Field**

20        This invention relates to an apparatus and method for delivering oxygen-supersaturated physiologic solutions during clinical procedures, such as angioplasty.

**Related Art**

25        I have previously disclosed methods for delivering oxygen-supersaturated solutions into blood without cavitation. Such solutions contain high levels of oxygen.

30        In clinical angioplasty, it would be desirable to replace arterial blood beyond an angioplasty device with a physiologic solution containing oxygen. However,

-2-

when the oxygen is dissolved under pressures greater than about 1 bar, there is an increased risk of bubble formation and may lead to potential oxygen toxicity.

Summary Of The Invention

5 This invention relates to an apparatus and method for delivering oxygen-supersaturated physiologic solutions during angioplasty to replace arterial blood without bubble formation.

10 A collapsible container of a physiologic solution is disposed within a hollow, gas-tight vessel so that a space between the container and the vessel is created. A trocar is located within the container, the trocar being in communication with a supply of oxygen under pressure. The trocar drives the oxygen into 15 solution to prepare the oxygen-supersaturated solution within the container.

An inlet port is provided in the vessel in communication with the space and the supply of oxygen for pressurizing the space. The supply is in 20 simultaneous communication with the space external to the container within the vessel and with the physiologic solution.

To control the flow of undissolved oxygen from the space, an adjustable space exit valve is connected 25 to the vessel. By adjustment, the exit valve permits a flow of oxygen from the space at a higher rate than that at which oxygen is introduced into the solution.

-3-

An angioplasty catheter having a central channel lies in communication with the oxygen-supersaturated physiologic solution, which is infused into the artery without bubble formation.

5

Brief Description Of The Drawings

Figure 1 is a schematic illustration of an apparatus for preparing an oxygen-supersaturated solution; and

10

Figure 2 illustrates a configuration of the apparatus wherein the oxygen-supersaturated solution is delivered to a lumen of a blood vessel to replace arterial blood beyond an angioplasty device.

Best Mode(s) For Practicing The Invention

1. The Apparatus

15

Turning first to Figs. 1-2 of the drawing, there is depicted an apparatus 10 for delivering an oxygen-supersaturated physiologic solution 12 into a lumen of a blood vessel 16 to replace arterial blood beyond an angioplasty catheter 18 during clinical angioplasty. The apparatus 10 operates in two modes: (1) preparation of the oxygen-supersaturated solution (Fig. 1); and (2) delivery of the oxygen-supersaturated solution to the angioplasty catheter (Fig. 2).

20

In Fig. 1, there is depicted an apparatus 10 for delivering the oxygen-supersaturated physiologic solution 12 into a lumen 14 of a blood vessel 16 to replace arterial blood beyond an angioplasty catheter 18

-4-

during clinical angioplasty. The apparatus 10 includes a hollow, gas-tight vessel 20 within which is disposed a collapsible container 22 of initially oxygen-depleted physiologic solution 12. A space 24 exists between the 5 container 22 and the vessel 20 into which the collapsible container 22 may expand.

A trocar 26 is sealingly inserted into the vessel 20 and the container 22. Within the container 22, a perforated section of the trocar 26 extends below 10 a meniscus of the physiologic solution 12 which occupies the container 22. Upon connection with a supply 28 of oxygen under pressure, the trocar 26 drives the oxygen into the solution, thereby preparing an oxygen-supersaturated solution 30 within the container 22.

15 An inlet port 32 is provided in the vessel 20 in communication with the space 24 and the supply 28 of oxygen. By the use of suitable valving which will be described in greater detail below, a single supply 28 of oxygen creates a differential in gas pressure across the 20 walls of the container 22 within the gas-tight vessel 20.

Also connected to the vessel 20 in communication with the space 24 is an adjustable space 25 exit valve 36, the valve 36 enabling control to be exercised over the flow of oxygen from the space 24 so that the oxygen may leave the space 24 at a higher rate than that at which oxygen is introduced into the solution.

A fluid control means 38, such as a valve 30 having a T-junction, has a gas-opened state 40 (Fig. 1)

-5-

in which the oxygen may flow from the supply 28 into the trocar 26. In a gas-closed state 42 (Fig. 2) the oxygen supply 28 is isolated and the oxygen-supersaturated solution flows from the trocar 26 to the angioplasty 5 catheter 18.

The angioplasty catheter 18 has a central channel 20 in communication with the oxygen-supersaturated physiologic solution 12, which is infused into the blood vessel without bubble formation beyond 10 the angioplasty catheter 18.

The experimental apparatus and procedure depicted in Fig. 1 will now be described in more detail.

The supply 28 of oxygen is typically housed at a pressure at or below about 2500 psi. Near the tank's 15 outlet, an oxygen supply regulator 44 (adjustable resistance) is provided for reduction of supply pressure to about 15-30 psi. Thus, the oxygen pressure inside the vessel 20 and outside the container 22 that occupies the space 24 is of the order of 15-30 psi. Typically, 20 the regulator 44 is provided with gauges or other means which signal the pressure of oxygen supplied to the container 22 and the space 24.

The regulator 44 is connected to a trocar 26 via a tube, which has a branch that leads into the inlet 25 port 32 provided in the vessel 20. Branching from the tube is a section along which oxygen may pass toward a stop cock or other fluid control means 38 which when in a gas-opened state (Fig. 1), allows the oxygen to pass into the trocar 26.

-6-

If desired, the trocar 26 may be provided with multiple holes for delivery of the oxygen into solution in the container 22 under pressure. The trocar 26 is also used for ejection of the oxygen-supersaturated 5 solution from the container 22 in a manner to be described below.

Upon entry into the physiologic solution from the trocar 26, oxygen bubbles rise within the oxygen-depleted physiologic solution in the container 22 to become dissolved under pressure therein, the thereby to form the oxygen-enriched physiologic solution. The container 22 preferably has a capacity of about 1-2 liters. 10

If desired, a clear, non-oxygen permeable 15 plastic tape or adhesive sheet (not shown) may be applied to the external surface of the container 22 within the gas-tight vessel 20. The plastic tape or film disposed about the outside of the container 22 tends to prevent oxygen diffusion through the container 20 22 into solution.

A port 46 may be provided for the injection of ions, drugs, and the like into the container 22 before emplacement of the container 22 within the vessel 20.

To provide an escape path for undissolved 25 oxygen which occupies a volume above the meniscus of physiologic solution and within the container 22, a passage 48 is provided. A container exit valve 36 may be connected thereto for controlling the rate of escape of oxygen venting from the container 22.

-7-

The adjustable space exit valve 34 communicates with a pressure sensing means 52 that enables pressure inside the space within the vessel 20 to be monitored. A differential pressure sensing means 50 is provided to signal the pressure difference between oxygen leaving the space 24 and the container 22.

The space exit valve 34 allows oxygen to vent at a higher flow rate from the space 24 than the bubble flow rate within the container. This creates a pressure outside the container in the space that is a few psi below the pressure within the container 22.

A preferable construction of the apparatus of the present invention comprehends the vessel 20 being fabricated from a clear gas-tight material such as an acrylic, or polycarbonate, or the like. Preferably, the vessel is cylindrical for uniformity of pressure distribution. Clear end plates 62,64 seal the vessel 20 so that it is gas-tight. If desired, latches may be provided for retaining the end plates (not shown) in relation to the cylinder.

Turning now to Fig. 2, there will be described in greater detail the apparatus which is used to deliver the oxygen-supersaturated solution that is prepared as illustrated in Fig. 1. The regulator 44 is adjusted so that the outlet pressure from the oxygen supply is within the 20-200 psi range. The valves 36 and 38 are closed to oxygen flow so that the fluid control means 38 is in its gas-closed state 42. The pressure differential gauge 54 indicates a reading of about 0 psi, while pressure gauge 52 indicates a pressure in the space 24 to be about 20-200 psi.

-8-

The pressure of oxygen (about 20-200 psi) forces the undissolved gas out of the container and provides a hydrostatic pressure to: (a) dissolve all bubbles; and (b) deliver the now oxygen-supersaturated solution at a desired flow rate through the delivery tube 56, which is preferably fabricated from a plastic pressure tubing, or the like.

Various monitoring parameters are derived. If desired, a pressure sensor 58 may be provided in communication with the delivery tube 56. A flow probe 60 may also be provided, as may a bubble detector 62.

A portion of the flow passing along the delivery tube is provided to permit a sample (about 1-5% of mainstream) for siphoning a specimen for analysis. This solution passes through a sensor 68 for detecting the partial pressure of oxygen within the oxygen-supersaturated physiologic solution.

As the delivery tube and its effluents pass through a heat exchanger 70, a thermal equilibrium is attained in which the oxygen-supersaturated physiologic solution is maintained about 37° before passing along a section of thermally insulated tube 80 and to the central channel 20 of the angioplasty catheter 18.

Conventionally, the angioplasty catheter 18 includes a balloon inflation port 74 and a balloon 76, which is inflated within a blood vessel such as a coronary artery 16. Passage of the oxygen-supersaturated physiologic solution along the central channel of the catheter 18 permits the oxygen-

-9-

supersaturated solution to fill the lumen 14 of the coronary artery 16 distal to the balloon 76, as shown.

As schematically illustrated in Fig. 2, a monitoring means 80 is provided which senses and displays values for pressure as detected at the pressure sensor 58; flow rate, as detected at the flow probe 60; oxygen partial pressure, as detected at the oxygen pressure sensor 68; an ECG readout via an ECG means 82, and signals (intra coronary) transmitted by the angioplasty guide wire. If desired, an electronic shut-off means 78 is provided, wherein flow is truncated if the monitored parameters fail to lie within acceptable ranges. Conventionally, the monitoring device 80 includes a manual stop button and a start button which, opens the electronic shut-off valve 78. Optionally, a timer may be provided wherein the duration of infusion may be set.

## 2. The Method

During angioplasty catheter operations, when a coronary artery is temporarily occluded during clinical angioplasty, such as during balloon angioplasty, delivery of a physiologic solution, containing oxygen dissolved at 2-3 bar, at a liquid flow rate of 10 to 60 mL/min into the vessel beyond the angioplasty device will greatly reduce or even abolish myocardial ischemia. At such pressures and flow rates, the risk of bubble formation and potential oxygen toxicity is reduced.

Thus, addition of oxygen-supersaturated solutions to flowing arterial blood is performed

-10-

optimally when a high concentration, on the order of 1-3 mL O<sub>2</sub>/g, is used, thereby necessitating a low liquid flow rate (1-2 mL/min for an average coronary artery having a blood flow rate of about 100 cc/min) to achieve a net 5 O<sub>2</sub> concentration in the blood of about 2-3 bar.

As shown in Figures 1 and 2, the method provides a physiologic solution containing 2-3 bar of dissolved oxygen to a coronary artery during angioplasty in a simple, safe, and effective manner.

10 The container 22 has a physiologic solution in a volume of about 1 liter of normal saline to which other components, such as potassium, calcium, magnesium ions, glucose, buffers, etc., can be added.

15 The vessel 20 is, for example, an acrylic cylinder, approximately 6 in. in internal diameter with a wall thickness of about 1/2 in. It can be pressurized, after sealing the ends with plastic plates and o-rings, to greater than 200 psi.

20 Prior to placement in the vessel, the surface of the bag may be covered with a translucent plastic film which is relatively impermeable to oxygen. For example, application of clear packaging tape to the outside surface of the bag is effective for this purpose.

25 After placement of the bag 22 in the vessel 20, a dip trocar or trocar 26 within the bag is used to bubble oxygen at a target partial pressure, on the order of 2-3 bar. The space 24 external to the container is pressurized by the same oxygen source that pressurizes

-11+

the trocar 26. Allowing oxygen to leak at a slightly faster flow rate from the space outside the bag compared to the bubble flow rate ensures that a differential pressure of a few psi is obtained which permits the flow 5 of oxygen through the trocar 26 at an appropriate rate.

Once the solution in the bag 22 has reached the target partial pressure of oxygen, flow through the dip trocar 26 is stopped and the oxygen pressure external to the bag is increased slightly to drive out 10 any pockets at the top of the bag. The same source of oxygen is then used to increase the oxygen pressure in the vessel 20 to provide hydrostatic pressure for achieving liquid flow rates required for the coronary artery application.

15 For example, pressures of about 30 to 60 psi can be used to deliver the oxygen supersaturated liquid at about 35 to 70 mL/min through the central channel 20 of an angioplasty catheter without the presence of a guide wire. Pressures of 50-150 psi can be used to 20 deliver the same flow rates when a guide wire is left in the central channel 20 of the angioplasty catheter.

25 The hydrostatic pressure serves not only to drive the solution at an appropriate flow rate, but also forces any oxygen bubbles into solution, so that no bubbles are delivered into the artery.

Additional hydrostatic pressure can be applied to be oxygen-enriched fluid after it leaves the bag, so that a sufficiently high pressure can be achieved proximal to high resistance (such as a hollow guide 30 wire, or small silicon capillary tube) encountered in an

-12-

exit channel. The additional hydrostatic pressure could be applied by one or a variety of water pumps, such as a air-driven water pump.

5                 The relatively small channel (0.020" or smaller in most PTCA catheters) within the angioplasty catheter for delivery of the solution provides flow resistance means 84 a suitably high resistance which stabilizes the meniscus solution during infusion into a blood vessel.

10               As is apparent from the above description, a small tank of oxygen can be used to both oxygenate a physiologic solution and provide the hydrostatic pressure for delivering the solution through the catheter.

15               Maintenance of sterility of the solution is simple with this system, since all tubing and fittings can be made inexpensively and, therefore, are disposable after use..

20               A few additional features can be added to the tubing at the outlet of the system to control the parameters of interest. Both pressure and flow can be monitored continuously and po<sub>2</sub> can be monitored either from a side port or in a small tributary or side stream siphoned from the delivery tubing. Should pressure, 25 flow, or po<sub>2</sub>, fall outside of expected limits, the flow could be stopped with automatic electronic controls.

By monitoring the ECG from the distal end of a standard guide wire within the angioplasty catheter, for example, with an alligator clip connected to a "V"

-13-

lead of a 12 lead ECG machine, intra-cardiac electrical activity can be used to determine if bubbles are produced inadvertently.

5            Electrical impedance in blood is greatly reduced by the presence of gas bubbles, as I recently observed in an in vivo dog study. Even a few bubbles in a coronary artery, at a level which can be tolerated for a few minutes without sequelae, reduce the ECG signal from >20 mV to 0 within 2 seconds.

10           The automatic shutoff mechanism 78 is incorporated in the oxygen-supersaturated solution delivery system. It is based on sensing a fall in the intra-cardiac ECG signal as monitored from the angioplasty guide wire. Thus, the delivery system is  
15           highly safe and reliable.

20           A similar delivery system could easily be employed for providing cardioplegia solutions for protection of the myocardium during cardio-pulmonary surgical procedures. In that environment, a catheter would be inserted typically in the aortic root for intermittent delivery of either cold or warm cardioplegia solution which is supersaturated with oxygen, typically at about 2-3 bar dissolved oxygen pressure.

25           The improved oxygen delivery afforded by the oxygen-enriched cardioplegia solution would reduce injury to the myocardium as a result of reperfusion upon completion of cardio-pulmonary bypass. As a result, myocardium performance would be enhanced, compared to

-14-

the use of cardioplegia solutions which are not enriched with oxygen.

5           The artery of interest is not restricted to the coronary. It could be any artery in the body for delivering the oxygen-supersaturated fluid, such as cerebral arteries or for treatment of patients with a stroke or for arteries that supply tumors for enhancing radiation therapy of tumors with the oxygen-enriched fluid.

10           The oxygen-enriched fluid can be delivered to any appropriate catheter that stabilizes the fluid during delivery.

15           Having above indicated a preferred embodiment of the present invention, it will occur to those skilled in the art that modifications and alternatives can be practiced within the spirit of the invention. It is accordingly intended to define the scope of the invention only as indicated in the following claims.

-15-

I CLAIM:

1. An apparatus for delivering an oxygen-supersaturated physiologic solution into a lumen of a blood vessel to replace arterial blood beyond a catheter comprising:
  - 5 a hollow, gas-tight vessel;
  - a collapsible container of physiologic solution disposed within the vessel so that a space between the container and the vessel is provided;
  - 10 a trocar sealingly inserted into the vessel and the container, the trocar being in communication with a supply of oxygen under pressure for driving the oxygen into solution via the trocar, thereby preparing oxygen-supersaturated solution within the container;
  - 15 an inlet port provided in the vessel in communication with the space and the supply of oxygen for pressurizing the space;
  - 20 an adjustable container exit valve connected to the container, the container exit valve controlling the flow of undissolved oxygen from the container;
  - 25 an adjustable space exit valve connected to the vessel, the space exit valve controlling the flow of oxygen from the space so that oxygen leaves the space at a higher rate than that at which oxygen is introduced into the solution; and
  - 30 a fluid control means having a gas-opened state in which the oxygen may flow from the supply into the trocar and a gas-closed state in which the supply is isolated and the oxygen-supersaturated solution may flow from the trocar to the catheter so that the oxygen-supersaturated solution is infused into the blood vessel without bubble formation.

-16-

2. The apparatus of Claim 1, further comprising:

an oxygen-impermeable sheet applied to an external surface of the container.

5 3. The apparatus of Claim 1, further comprising:

a port provided within the container for injecting ions, drugs, and the like into the container before emplacement of the container within the vessel.

10 4. The apparatus of Claim 1, wherein the container exit valve provides an escape path for undissolved oxygen.

15 5. The apparatus of Claim 1, wherein the space exit valve permits pressure inside the space to be regulated so that a pressure differential is created between oxygen leaving the space and the container whereby a pressure outside the container in the space is less than the pressure within the container.

20 6. The apparatus of Claim 1, wherein the vessel is cylindrical for uniformity of pressure distribution.

7. The apparatus of Claim 1, further comprising:

25 a delivery tube that connects the trocar with the angioplasty catheter.

8. The apparatus of Claim 7, further comprising:

-17-

a pressure sensor in communication with the delivery tube for sensing the pressure at which the oxygen-supersaturated solution is delivered to the angioplasty catheter.

5           9. The apparatus of Claim 7, further comprising:

a flow probe which measures the flow rate of oxygen-supersaturated solution delivered to the angioplasty catheter.

10          10. The apparatus of Claim 7, further comprising:

a bubble detector in communication with the delivery tube for detecting bubbles in the oxygen-supersaturated solution before delivery to the angioplasty catheter.

11. The apparatus of Claim 7, further comprising:

a sensor for detecting the partial pressure of oxygen within the oxygen-supersaturated physiologic solution before delivery to the angioplasty catheter.

12. The apparatus of Claim 7, further comprising:

a heat exchanger for creating and maintaining a temperature in the oxygen-supersaturated physiologic solution of about 37°C before delivery to the angioplasty catheter.

13. The apparatus of Claim 12, further comprising:

-18-

a thermally insulated section of tubing which connects the heat exchanger with the angioplasty catheter.

14. The apparatus of Claim 13, further  
5 comprising:

a safety valve in communication with the thermally insulated section whereby flow of the oxygen-supersaturated solution from the heat exchanger is shut off if monitored parameters are not in an acceptable  
10 range.

15. The apparatus of Claim 14, further comprising:

means for generating an ECG signal connected to a guide wire of the angioplasty catheter, based on  
15 intra-coronary observation.

16. The apparatus of Claim 1, wherein the physiologic solution comprises:

a saline solution.

17. The apparatus of Claim 16, further  
20 comprising an additive to the saline solution, the additive being selected from the group consisting of potassium, calcium, magnesium ions, glucose, buffers, and mixtures thereof.

18. The apparatus of Claim 1, further  
25 comprising:

a flow resistance means disposed within the angioplasty catheter, whereby a suitably high resistance is afforded which stabilizes the oxygen-supersaturated

-19-,

physiologic solution during infusion into the blood vessel.

19. A method for delivering an oxygen-supersaturated physiologic solution into a lumen of a blood vessel to replace arterial blood beyond an angioplasty device during clinical angioplasty, comprising:

5 placing a collapsible container of a physiologic solution within a hollow, gas-tight vessel  
10 so that a space between the container and the vessel is provided;

locating a trocar within the container, the trocar being in communication with a supply of oxygen under pressure;

15 dissolving the oxygen into the solution under pressure to prepare the oxygen-supersaturated solution within the container;

20 controlling respective oxygen flow rates into the solution and from the space so that the oxygen leaves the space at a higher rate than that at which oxygen is introduced into the solution; and

delivering the oxygen-supersaturated solution to an angioplasty catheter so that the solution is infused into the lumen without bubble formation.

25 20. The method of Claim 19, wherein the step of delivering the oxygen-supersaturated solution comprises:

30 infusing the solution under a pressure of about 2-3 bar at a liquid flow rate of about 10-60 mL/min.

-20-

21. The method of Claim 20, wherein the step of delivering the oxygen-supersaturated solution comprises:

5 infusing the solution at a concentration of about 1-3 mL O<sub>2</sub>/g.

22. The method of Claim 21, further comprising:

10 supplementing the physiologic solution within the container with an additive selected from the group consisting of potassium, calcium, magnesium ions, glucose, buffers, and mixtures thereof.

23. The method of Claim 19, further comprising:

15 arresting flow of oxygen through the trocar when the oxygen-supersaturated physiologic solution has reached a target partial pressure of oxygen;

increasing the oxygen pressure within the space to drive out any pockets lying above a meniscus of the solution within the container; and

20 increasing oxygen pressure in the space to provide hydrostatic pressure for achieving liquid flow rates required for coronary artery applications.

1/2





FIG. 1

10

2/2



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/08083

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :A61M 15/00, 37/00; B65D 35/28, 83/00  
US CL :128/203.12; 225/95, 400.7; 604/24

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 128/203.12; 225/95, 400.7; 604/24

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
**NONE**

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

**NONE**

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	US, A, 5,507,280 (HENKIN ET AL.) 16 April 1996, see entire document.	1-23
A	US, A, 4,770,168 (RUSZ ET AL.) 13 September 1988, see entire document.	1-23
A	US, A, 5,119,807 (ROBERTS) 09 June 1992, see entire document.	1-23
A	US, A, 4,039,639 (KANKEL ET AL.) 02 August 1977, see entire document.	1-23
A	US, A, 5,059,182 (LAING) 22 October 1991, see entire document.	1-23
A	US, A, 5,124,088 (STUMPHAUZER) 23 June 1992, see entire document.	1-18

Further documents are listed in the continuation of Box C.



See patent family annex.

•	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A*	document defining the general state of the art which is not considered to be part of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E*	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L*	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
*O*	document referring to an oral disclosure, use, exhibition or other means		
*P*	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

29 AUGUST 1996

Date of mailing of the international search report

26 SEP 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Faxsimile No. (703) 305-3590

Authorized officer

CHALIN SMITH

Telephone No. (703) 308-2988